Sanofi announces positive data for frexalimab product to treat multiple sclerosis

[May 31, 2023]  PARIS (Reuters) - French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple sclerosis in early 2024.

(Reporting by Sudip Kar-Gupta; Editing by Shri Navaratnam)
 

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

Sanofi logo at the company's headquarters during the annual results news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier